AGENUS INC (AGEN)       1.96  -0.17 (-7.98%)

1.96  -0.17 (-7.98%)

US00847G7051 - Common Stock - After market: 1.95 -0.01 (-0.51%)

News Image
8 days ago - InvestorPlace

7 Penny Stocks That Actually Have a Buy Rating

Penny stocks are always a risky proposition. However, investors can still find penny stocks with buy ratings right now.

News Image
15 days ago - Agenus Inc.

Agenus Initiates Botensilimab Phase 2 ACTIVATE Trials in Advanced MSS Colorectal Cancer and Advanced Melanoma

Phase 2 ACTIVATE trials to advance globally in metastatic patients who have progressed on available therapiesBotensilimab, alone and in combination with...

News Image
15 days ago - Agenus Inc.

Agenus Makes Senior Regulatory and Clinical Appointments

Patricia Carlos named Chief Regulatory, Quality, and Safety OfficerTodd Yancey, MD named Senior Global Clinical Development, Medical Affairs and Commercial...

News Image
2 months ago - Agenus Inc.

Agenus Provides Corporate Update and Second Quarter 2022 Financial Report

Botensilimab (Fc-enhanced CTLA-4)/balstilimab (PD-1) combination data presented at the 2022 ESMO World GI Congress demonstrated remarkable clinical...

News Image
2 months ago - Agenus Inc.

Agenus to Participate at BTIG Biotechnology Conference

LEXINGTON, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed...

News Image
2 months ago - Agenus Inc.

Agenus to Provide Corporate Update and Second Quarter 2022 Financial Report

Conference Call on Tuesday, August 9, 2022 at 8:30 a.m. ET...

News Image
2 months ago - Agenus Inc.

Agenus to Provide Corporate Update and Second Quarter 2022 Financial Report

Conference Call on Tuesday, August 9, 2022 at 8:30 a.m. ET

News Image
3 months ago - Agenus Inc.

Agenus to Participate at William Blair’s Biotech Focus Conference

LEXINGTON, Mass., June 30, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed...

News Image
3 months ago - Agenus Inc.

Agenus Shows Unprecedented Activity for Botensilimab/Balstilimab Combination in Microsatellite Stable Colorectal Cancer at ESMO World GI Congress

Overall response rate of 24%, and disease control rate of 73%, in heavily pre-treated patients with a median of 4 prior lines of therapyResponses to...

News Image
4 months ago - Agenus Inc.

Agenus Advances Portfolio with 6 Clinical Collaborations

LEXINGTON, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics...

News Image
4 months ago - Agenus Inc.

Agenus Announces Virtual Annual Shareholders Meeting

LEXINGTON, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed...

News Image
4 months ago - Agenus Inc.

Agenus to Participate at Jefferies Healthcare Conference

LEXINGTON, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed...

News Image
4 months ago - Agenus Inc.

Agenus Announces Late-Breaking Oral Presentation at ESMO-GI and Strategies to Advance Botensilimab

Data to be Presented in Heavily Pretreated MSS-CRCSpeed and Innovation Core to Development StrategyReduction of 20% in 2022 Operating Costs LEXINGTON,...

News Image
5 months ago - Agenus Inc.

Agenus Corporate Update and First Quarter 2022 Financial Report

Botensilimab data to be presented and Phase 2 trials to launch.AGEN1571 (ILT2) clinical trials to commence and data presented at AACR.AGEN2373 progressing...

News Image
5 months ago - Agenus Inc.

Agenus to Provide Corporate Update and First Quarter 2022 Financial Report

Conference Call on Tuesday, May 10, 2022 at 8:30 a.m. ET...

News Image
6 months ago - Agenus Inc.

Agenus Presents Data on AGEN1571 (anti-ILT2) at AACR and Announces IND Clearance

First data presentation on AGEN1571 shows strong adaptive and innate immune responsesPreclinical data indicate superior performance to the only...

News Image
6 months ago - Agenus Inc.

Agenus’ CD137 Agonist (AGEN2373) Advances in the Clinic, Triggering Milestone Payment from Gilead

LEXINGTON, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics...